Navigation Links
Celldex Therapeutics Announces Orphan Drug Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma Multiforme
Date:12/7/2007

reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

This communication may be deemed to be solicitation material in respect of the proposed merger of AVANT and Celldex. In connection with the proposed merger, AVANT and Celldex intend to file relevant materials with the SEC, including AVANT's joint registration statement/proxy statement on Form S-4. SHAREHOLDERS OF AVANT ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH THE SEC, INCLUDING AVANT'S PROXY STATEMENT, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders will be able to obtain the documents free of charge at the SEC's web site, http://www.sec.gov, and AVANT shareholders will receive information at an appropriate time on how to obtain transaction-related documents for free from AVANT. Such documents are not currently available. Participants in the Solicitation The directors and executive officers of AVANT and Celldex may be deemed to be participants in the solicitation of proxies from the holders of AVANT common stock in respect of the proposed transaction. Information about the directors and executive officers of AVANT is set forth in the proxy statement for AVANT's most recent 10-K, which was filed with the SEC on March 16, 2007. Investors may obtain additional information regarding the interest of AVANT and its directors and executive officers, and Celldex and its directors and executive officers in the proposed transaction by reading the proxy statement regarding the acquisition when it becomes available.


'/>"/>
SOURCE Celldex Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... GLENWOOD, Ill. , May 20, 2013 ... leader in personal and environmental radiation measurement and monitoring, ... accessories, announced today that its Board of Directors declared, ... quarterly cash dividend of $0.55 per share for the ... paid on July 3, 2013, to shareholders of record ...
(Date:5/20/2013)... , May 20, 2013   National Community ... Hoey , RPh, MBA issued the following statement ... Associates regarding Medicare Part D "preferred pharmacy" drug ... offering patients the plan,s lowest advertised co-payments: ... Medicare and MedPAC , 16 ...
(Date:5/20/2013)...  TRACE International today released its Global Enforcement ... against individuals and government or business entities for bribery ... 2012 is the third in an annual series ... "Although the number of outbound enforcement actions fell ... priority," said Alexandra Wrage , TRACE ...
Breaking Medicine Technology:Landauer, Inc. Declares Regular Cash Dividend 2Poll: Over One Million Seniors Have Problems with Medicare 'Preferred Pharmacy' Drug Plans 2Poll: Over One Million Seniors Have Problems with Medicare 'Preferred Pharmacy' Drug Plans 3Poll: Over One Million Seniors Have Problems with Medicare 'Preferred Pharmacy' Drug Plans 4TRACE Releases 2012 Global Enforcement Report 2TRACE Releases 2012 Global Enforcement Report 3
... Elsevier, the world-leading publisher of ... announced today that its 2012 eBook Frontlist collections ... Elsevier,s online platform for scientific content. This release ... depth of the eBook collection on SciVerse ScienceDirect. ...
... 2011 Baxa Corporation , a leading provider ... has released a software upgrade for its ExactaMix® ... 14 updates that provide Directors of Pharmacy with enhanced ... worldwide use ExactaMix 2400 (EM2400) and ExactaMix 1200 (EM1200) ...
Cached Medicine Technology:Elsevier Announces New 2012 Frontlist eBooks Collection on SciVerse ScienceDirect Available for Advance Purchase 2Elsevier Announces New 2012 Frontlist eBooks Collection on SciVerse ScienceDirect Available for Advance Purchase 3Baxa Corporation Bolsters Patient Safety With ExactaMix® Compounder Software Upgrade 2Baxa Corporation Bolsters Patient Safety With ExactaMix® Compounder Software Upgrade 3Baxa Corporation Bolsters Patient Safety With ExactaMix® Compounder Software Upgrade 4
(Date:5/21/2013)... 2013, PHILADELPHIA ─ The negative effects of poorly ... performance in urban schoolchildren has been confirmed in ... been recognized that missed sleep and school absences ... our study is the first to explore the ... in real time, prospectively, using both objective ...
(Date:5/21/2013)... physical activity appears to be an independent predictor ... pulmonary disease (COPD) will end up being hospitalized, ... in Connecticut. The study also corroborates an earlier ... an increased incidence of hospitalizations among patients with ... be presented at the ATS 2013 International Conference. ...
(Date:5/21/2013)... 2013, PHILADELPHIA ─ A novel approach to obstructing ... of asthma has shown promise in a Phase ... , Their research will be presented at the ... simultaneously online in the New England Journal ... trial tested the efficacy and safety of the ...
(Date:5/21/2013)... PHILADELPHIA─Treatment with an Alpha-1 proteinase inhibitor (A1-PI), a ... breakdown and protects the lung,s elasticity, is effective ... with Alpha-1 antitrypsin deficiency (AATD), a life-threatening genetic ... the 2013 American Thoracic Society International Conference. , ... the loss of lung tissue as measured by ...
(Date:5/21/2013)... After the success of its inaugural 1,000 lb. ... Body Boot Camp Goderich will be hosting its 2nd Annual ... Goderich fitness center located at 199 Anglesea Street Goderich, ... goal is to inspire and motivate local community residents to ... The fee to participate is discounted to $40 for the ...
Breaking Medicine News(10 mins):Health News:Asthma symptoms impair sleep quality and school performance in children 2Health News:Exercise levels may predict hospitalizations in COPD population 2Health News:Monoclonal antibody appears effective and safe in asthma Phase IIa trial 2Health News:Monoclonal antibody appears effective and safe in asthma Phase IIa trial 3Health News:Treatment with A1-PI slows the progression of emphysema in Alpha-1 antitrypsin deficiency 2Health News:Treatment with A1-PI slows the progression of emphysema in Alpha-1 antitrypsin deficiency 3Health News:Goderich Fitness Center Promotes 2nd Annual 1,000 lb. Meltdown Challenge to Fight Obesity With All Proceeds Raised Going to Local Charity 2Health News:Goderich Fitness Center Promotes 2nd Annual 1,000 lb. Meltdown Challenge to Fight Obesity With All Proceeds Raised Going to Local Charity 3
... of Public Health reported that most of the flu shot ... to the department, 94% of the state's total order has ... 24. Over 1.7 million vaccines will be stocked that includes ... Centers for Disease Control and Prevention revealed that this flu ...
... The World Health Organization (WHO), on Friday, had initiated the ... prevent infections associated //with Health care practices. WHO said that ... costs but also will save lives. ,It is ... by the infections caused by the hospitals, which are mainly ...
... are more likely to develop certain types of cancer ... // ,Grace LeMasters and colleagues at the ... fire fighters from 32 previously published scientific studies to ... of their profession, reported science portal EurekAlert. ...
... recent study revealed that consuming just two cups of green ... Texas in collaboration with their counterparts in the UK carried ... online edition of the Journal of Allergy and Clinical Immunology. ... (EGCG) present in green tea has the ability to block ...
... disease are alarming. According to a news release by McGill ... Canada and 8,500 deaths from the disease are expected every ... deaths, as reported by the Centers for Disease Control and ... and 16,000 deaths. ,However, here is some good ...
... the eyes can diagnose cerebral malaria in children, according ... complication where the Plasmodium falciparum parasite infects capillaries that ... to detect as patients can be unconscious and have ... ratio in cerebral malaria is 25-50 percent, reported science ...
Cached Medicine News:Health News:The Anti-HIV Properties Of Green Tea Uncovered 2
... Helmer PC1200 Platelet Incubators ... your laboratory counter top. These ... institution to have the security ... environment without taking up a ...
The PC4200i is the largest capacity platelet incubator available. It features a built-in agitator with a capacity of 396 random bags (132 apheresis)....
... rotators and agitators for continual ... set at 22C (71F) or ... (59F to 104F). Uniformity is ... bottom. Recorder is standard on ...
An enzyme-linked immuno-sorbent assay for the detection and quantitation of anti-tissue Transglutaminase in serum of patients with Celiac Disease and Dermatitis Herpetiformis....
Medicine Products: